Risk Factors for Acute Gastroenteritis Among Patients Hospitalized in 5 Veterans Affairs Medical Centers, 2016-2019.

acute gastroenteritis hospitalized norovirus risk factors severe gastroenteritis

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 08 02 2022
accepted: 22 07 2022
entrez: 11 8 2022
pubmed: 12 8 2022
medline: 12 8 2022
Statut: epublish

Résumé

In the United States, ∼179 million acute gastroenteritis (AGE) episodes occur annually. We aimed to identify risk factors for all-cause AGE, norovirus-associated vs non-norovirus AGE, and severe vs mild/moderate AGE among hospitalized adults. We enrolled 1029 AGE cases and 624 non-AGE controls from December 1, 2016, to November 30, 2019, at 5 Veterans Affairs Medical Centers. Patient interviews and medical chart abstractions were conducted, and participant stool samples were tested using the BioFire Gastrointestinal Panel. Severe AGE was defined as a modified Vesikari score of ≥11. Multivariate logistic regression was performed to assess associations between potential risk factors and outcomes; univariate analysis was conducted for norovirus-associated AGE due to limited sample size. Among 1029 AGE cases, 551 (54%) had severe AGE and 44 (4%) were norovirus positive. Risk factors for all-cause AGE included immunosuppressive therapy (adjusted odds ratio [aOR], 5.6; 95% CI, 2.7-11.7), HIV infection (aOR, 3.9; 95% CI, 1.8-8.5), severe renal disease (aOR, 3.1; 95% CI, 1.8-5.2), and household contact with a person with AGE (aOR, 2.9; 95% CI, 1.3-6.7). Household (OR, 4.4; 95% CI, 1.6-12.0) and non-household contact (OR, 5.0; 95% CI, 2.2-11.5) with AGE was associated with norovirus-associated AGE. Norovirus positivity (aOR, 3.4; 95% CI, 1.3-8.8) was significantly associated with severe AGE. Patients with immunosuppressive therapy, HIV, and severe renal disease should be monitored for AGE and may benefit from targeted public health messaging regarding AGE prevention. These results may also direct future public health interventions, such as norovirus vaccines, to specific high-risk populations.

Sections du résumé

Background UNASSIGNED
In the United States, ∼179 million acute gastroenteritis (AGE) episodes occur annually. We aimed to identify risk factors for all-cause AGE, norovirus-associated vs non-norovirus AGE, and severe vs mild/moderate AGE among hospitalized adults.
Methods UNASSIGNED
We enrolled 1029 AGE cases and 624 non-AGE controls from December 1, 2016, to November 30, 2019, at 5 Veterans Affairs Medical Centers. Patient interviews and medical chart abstractions were conducted, and participant stool samples were tested using the BioFire Gastrointestinal Panel. Severe AGE was defined as a modified Vesikari score of ≥11. Multivariate logistic regression was performed to assess associations between potential risk factors and outcomes; univariate analysis was conducted for norovirus-associated AGE due to limited sample size.
Results UNASSIGNED
Among 1029 AGE cases, 551 (54%) had severe AGE and 44 (4%) were norovirus positive. Risk factors for all-cause AGE included immunosuppressive therapy (adjusted odds ratio [aOR], 5.6; 95% CI, 2.7-11.7), HIV infection (aOR, 3.9; 95% CI, 1.8-8.5), severe renal disease (aOR, 3.1; 95% CI, 1.8-5.2), and household contact with a person with AGE (aOR, 2.9; 95% CI, 1.3-6.7). Household (OR, 4.4; 95% CI, 1.6-12.0) and non-household contact (OR, 5.0; 95% CI, 2.2-11.5) with AGE was associated with norovirus-associated AGE. Norovirus positivity (aOR, 3.4; 95% CI, 1.3-8.8) was significantly associated with severe AGE.
Conclusions UNASSIGNED
Patients with immunosuppressive therapy, HIV, and severe renal disease should be monitored for AGE and may benefit from targeted public health messaging regarding AGE prevention. These results may also direct future public health interventions, such as norovirus vaccines, to specific high-risk populations.

Identifiants

pubmed: 35949407
doi: 10.1093/ofid/ofac339
pii: ofac339
pmc: PMC9356693
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac339

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Références

J Epidemiol. 2016;26(4):216-23
pubmed: 26639752
Clin J Am Soc Nephrol. 2008 Sep;3(5):1487-93
pubmed: 18650409
Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):935-43
pubmed: 19319582
BMC Infect Dis. 2016 Aug 09;16:395
pubmed: 27507065
J Microbiol Immunol Infect. 2021 Oct;54(5):909-917
pubmed: 32943327
BMC Infect Dis. 2019 Feb 11;19(1):133
pubmed: 30744568
Clin Infect Dis. 2021 Nov 2;73(9):e2729-e2738
pubmed: 32584956
Expert Rev Vaccines. 2018 Sep;17(9):773-784
pubmed: 30092671
PLoS One. 2016 Jul 20;11(7):e0158822
pubmed: 27438335
N Engl J Med. 2013 Mar 7;368(10):971
pubmed: 23465122
Clin Infect Dis. 2021 Jul 1;73(1):e1-e8
pubmed: 32291450
Curr Opin Gastroenterol. 2004 Jan;20(1):16-21
pubmed: 15703615
Vaccine. 2012 Apr 27;30 Suppl 1:A173-8
pubmed: 22520128
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Nephrology (Carlton). 2010 Jun;15(4):471-5
pubmed: 20609100
Emerg Infect Dis. 2011 Jan;17(1):16-22
pubmed: 21192849
Epidemiol Infect. 2011 Nov;139(11):1676-86
pubmed: 21205382
BMC Public Health. 2020 Jul 21;20(1):1146
pubmed: 32693787
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Emerg Infect Dis. 2003 Dec;9(12):1563-70
pubmed: 14720397
Am J Trop Med Hyg. 2017 Sep;97(3):937-943
pubmed: 28722577
Clin Microbiol Infect. 2019 Apr;25(4):454-461
pubmed: 29964235
Clin Infect Dis. 2011 Feb 15;52(4):466-74
pubmed: 21258098
Epidemiol Infect. 2006 Feb;134(1):111-8
pubmed: 16409657
J Infect Dis. 2012 May 1;205(9):1374-81
pubmed: 22454468
Am J Epidemiol. 2001 Oct 1;154(7):666-74
pubmed: 11581101
BMC Public Health. 2020 Apr 5;20(1):445
pubmed: 32248812
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Curr Opin Gastroenterol. 2006 Jan;22(1):18-23
pubmed: 16319672
JMIR Public Health Surveill. 2021 Jan 22;7(1):e24502
pubmed: 33338028
Gastroenterol Clin North Am. 2012 Sep;41(3):677-701
pubmed: 22917171

Auteurs

Neha Balachandran (N)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jordan Cates (J)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Anita K Kambhampati (AK)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Vincent C Marconi (VC)

Atlanta VA Medical Center, Atlanta, Georgia, USA.

Alexis Whitmire (A)

Atlanta VA Medical Center, Atlanta, Georgia, USA.

Elena Morales (E)

Atlanta VA Medical Center, Atlanta, Georgia, USA.

Sheldon T Brown (ST)

James J. Peters VA Medical Center, Bronx, New York, USA.

Diki Lama (D)

James J. Peters VA Medical Center, Bronx, New York, USA.

Maria C Rodriguez-Barradas (MC)

Infectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Rosalba Gomez Moronez (RG)

Infectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Gilberto Rivera Domiguez (GR)

Infectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

David O Beenhouwer (DO)

VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.

Aleksandra Poteshkina (A)

VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.

Zlatko Anthony Matolek (ZA)

VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.

Mark Holodniy (M)

Department of Veterans Affairs, Public Health Surveillance and Research, Washington DC, USA.

Cynthia Lucero-Obusan (C)

Department of Veterans Affairs, Public Health Surveillance and Research, Washington DC, USA.

Madhuri Agarwal (M)

Department of Veterans Affairs, Public Health Surveillance and Research, Washington DC, USA.

Cristina Cardemil (C)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Umesh Parashar (U)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sara A Mirza (SA)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Classifications MeSH